Medical Cannabis Dosage Forms

Overview

Medical cannabis can be delivered as flower, oral oils, capsules, oromucosal products and other pharmaceutical presentations. Each dosage form changes dose precision, onset, bioavailability, patient usability and the manufacturing controls required.

Dosage-form selection

Dosage-form selection depends on the clinical indication, required onset speed, and patient ability to use the delivery method reliably — a fast-onset inhaled product suits acute symptom control, while an oral oil suits steady background dosing. Each format carries different manufacturing, stability and quality-control demands, meaning the choice of dosage form should be made early, before formulation work begins.

Switching dosage forms after initial development is rarely a simple like-for-like change: bioavailability, dose consistency and patient experience can all differ substantially between formats delivering the same nominal cannabinoid content. Manufacturers should validate each dosage form independently rather than assuming equivalence across formats.

Flower and inhaled delivery

Flower and inhaled delivery formats depend on consistent particle size, moisture content and cannabinoid distribution across the batch, since inhaled dosing is far less precise than oral or oromucosal routes. Vaporisation temperature affects which cannabinoids and terpenes are released, meaning device compatibility and heating profile are part of the quality specification, not just the plant material itself.

Across all dosage forms, the critical quality attribute is dose reproducibility — the patient must reliably receive a consistent, predictable amount of active cannabinoid regardless of format. This depends on manufacturing process control at least as much as on the properties of the starting material itself.

Oral oils and capsules

Manufacturing control begins with a clear material specification and traceability. Critical variables may include cultivar, harvest timing, drying conditions, extraction parameters, solvent exposure, temperature, oxygen, light and hold times. The relevant variables should be identified through risk assessment and linked to measurable quality attributes.

Equipment and facilities should be appropriate for the operation, cleanable, maintained and qualified to the extent justified by risk. Where processing crosses from agricultural handling into pharmaceutical manufacture, responsibilities and documentation at the GACP–GMP interface must be explicit.

Oromucosal products

Analytical control of medical cannabis dosage forms requires suitable sampling, qualified instruments, appropriate reference standards and methods capable of separating the analytes that matter. Results can be misleading when acidic and neutral cannabinoids are combined inconsistently, moisture correction is unclear, matrix effects are ignored or calculations are not standardised.

A specification should be clinically and process relevant rather than a list of every measurable parameter. Identity, assay, related substances or degradation indicators, microbiological quality, contaminants and physical attributes should be selected according to the product and route of administration.

Quality and human factors

Lifecycle control extends beyond initial release. Stability studies should represent the marketed packaging and storage conditions, while deviations, out-of-trend results and complaints should feed back into the risk assessment. Changes to cultivar, supplier, equipment, method, packaging or process parameters require impact assessment before implementation.

The strongest approach is conservative and transparent: define the product, control variability, validate the measurements, communicate uncertainty and avoid claims that outrun the evidence. This is the difference between a novelty-led product and a pharmaceutical-quality product.

Implementation checklist

Before finalising a dosage form, confirm it genuinely suits the intended clinical use — onset speed, dosing precision and patient ability to self-administer reliably. Verify dose consistency has been demonstrated across the batch through content uniformity testing, and that any delivery device has been validated for delivered-dose accuracy, not just nominal capacity. Check that stability data covers the specific dosage form, since formats are rarely interchangeable in their degradation behaviour.

Control framework

Practical sequence

References and primary guidance

1. European Commission, EudraLex Volume 4: EU Guidelines for Good Manufacturing Practice.
2. ICH Q9(R1), Quality Risk Management.
3. ICH Q10, Pharmaceutical Quality System.
4. European Pharmacopoeia, applicable general monographs and analytical chapters.

References should be checked against the current consolidated legislation, pharmacopoeial edition and competent-authority guidance before operational use.

Frequently asked questions

Related ECI reading

Educational content only. This page does not constitute medical, legal or regulatory advice.